Sector News

Wacker Chemie buys Dutch biotechnology plant

April 17, 2018
Energy & Chemical Value Chain

Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg S.à.r.l..

The Munich-based chemical company announced the acquisition today. For WACKER, maintaining SynCo’s existing customer relationships is a top priority. Moreover, WACKER is keeping on SynCo’s employees. Both parties have agreed not to disclose the purchase price.

“This strategic acquisition is a key step for our ongoing expansion in the high-growth biopharmaceuticals market,” explained Auguste Willems of WACKER’s Executive Board. “The new plant will enable us to satisfy robust market demand today and in the coming years – and to strengthen our position as a leading contract manufacturer of microbial-derived biopharmaceutical proteins.”

Founded in 2000, SynCo Bio Partners has some 110 employees and operates two fermentation lines with current capacities of 1,500 and 270 liters. These lines manufacture microbial-derived biopharmaceuticals, not only for clinical testing, but also for the commercial market. There is a further line of single-use fermenters, which provides additional and flexible production capabilities. SynCo’s service offering is rounded out with a “fill and finish” facility, which enables the complete manufacture of pharma-ceuticals from the active agent to the filled product. The facilities meet “Good Manufacturing Practice” (GMP) quality standards, and they have already been inspected by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and approved for the manufacture of specific pharmaceutical proteins.

“Expanding our production capacity strengthens our market position sustainably,” said Gerhard Schmid, president of WACKER BIOSOLUTIONS. “The additional fermentation lines double our current capacity, which increases our ability to produce key pharmaceuticals cost effectively, using advanced microbial techniques. We look forward to continuing the comprehensive support for SynCo’s existing customers, while also offering them the proprietary technologies of Wacker Biotech. The acquisition will significantly expand our portfolio of technologies and services.”

SynCo’s expertise in manufacturing live microbial biopharmaceuticals is a valuable complement to WACKER’s know-how as a full-service supplier. Live microbial products represent a promising new class of actives, offering innovative therapies for serious illnesses and new vaccines against cholera, for example.

Source: Wacker Biotech

comments closed

Related News

March 24, 2024

Thomas Gangl leaves Borealis

Energy & Chemical Value Chain

Appointed Borealis CEO in 2021, Thomas has led key initiatives including the sale of the nitrogen business, acquisitions of Rialti Spa and Integra Plastics AD, and Borouge’s IPO. He also made the final investment decision for the Borouge 4 plant, set to be the world’s largest polyolefin complex.

March 24, 2024

Chemours names Dignam permanent CEO

Energy & Chemical Value Chain

The Chemours Co. today named interim CEO Denise Dignam as the company’s permanent CEO and president, as well as a member of the board of directors, effective immediately. Dignam has been interim CEO since late February, when former CEO Mark Newman was placed on leave due to an internal investigation.

March 24, 2024

Neste merges three business lines into new Renewable Products unit

Energy & Chemical Value Chain

Neste Corp. (Espoo, Finland) has completed its organizational change process, announced on 1 November 2023. Neste informed that it will merge its three renewable business units into one Renewable Products business unit as well as restructure its functions to better support business-driven ways of working.

How can we help you?

We're easy to reach